Shisha Is the Most Valuable Player for Thousands of Bars and Cafés – New Research Shows
25.10.2024 19:06:00 CEST | Business Wire | Press release
AIR Group Limited, the world’s largest producer of shisha molasses, owner of the famous Al Fakher brand and the inventor of the OOKA, the world’s first charcoal free pod-based shisha system, has released new research on the role of shisha in microbusinesses such as bars and cafés in the Middle East, Europe and the United States.
The study involved hundreds of interviews with bar, restaurant and café owners and managers in the UAE, Saudi Arabia, Germany, Spain and the US.
On average, circa 8 in 10 of the businesses surveyed identified shisha as the highest margin product item in their venues.
According to Ronan Barry, Chief Corporate Affairs Officer of AIR Group, “This shows us that shisha is among the most equitable fast moving consumer goods (aka FMCG’s) in the world. In most FMCG and lifestyle product categories the majority of the value accrues to the brand owner with some scraps left over for the broader value chain. But in shisha, the value is more equitably distributed with the lion’s share going to the smallest businesses in the chain, those who serve the experience to the consumer.”
“We have long suspected that shisha is likely the Most Valuable Player (MVP) in the hospitality sector. These businesses enjoy margins on shisha of up to 95%, compared to about 5% on average in food.”
There are over a hundred thousand hospitality venues serving shisha and according to the sample surveyed by AIR, if these businesses did not serve shisha, their very survival would be in doubt. Almost half of survey respondents would close their doors if they were unable to offer shisha.
According to Garth Beer, who manages a shisha catering business providing shisha service to dozens of bars, restaurants and night clubs, “Shisha plays a critical role in drawing customers into the venue and in keeping them there. In some cases, its ‘come for the shisha, stay for the food and drink’ while in others its ‘come for the food, stay for a shisha’ and that the after-dinner shisha can be the difference between a profitable table and a non-profitable table.”
However, the boom of shisha remains unavailable to a majority of bars and restaurants due to the use of charcoal to heat the molasses and generate the cloud for the customers to enjoy. Charcoal is both a fire hazard and a source of toxic chemicals in indoor environments, requiring significant investments in fire safety and ventilation. AIR’s newest innovation, a revolutionary charcoal free, pod-based shisha system offers the opportunity for more microbusinesses to reap the benefits of shisha services because it removes charcoal and side streams smoke entirely, leaving a much cleaner shisha cloud for the consumer to enjoy. Already OOKA has been embraced by almost 250 bars and restaurants in Germany and in the UAE.
According to Mario, General Manager of a premium night club in Dubai “We, regrettably, had to exclude shisha from our club due to the smoke and fire safety concerns even though guests have been asking for it.
“We’ve had OOKA for a few months now and the feedback from our customers is fantastic. We’re on track to have a record season and it’s clear that OOKA will be a major contributor to that.”
AIR will continue to work with hospitality businesses around the world to support them in adopting shisha and OOKA and also in supporting the training of their staff to ensure that they can confidently offer the best customer experience in every serving.
About AIR (ADVANCED INHALATION RITUALS)
AIR is the market leader in the $19 billion global shisha market, with an aim to provide superior physical, emotional and mental benefits through inhalation. Launched in 1999 and headquartered in Dubai, the business has a multinational presence in over 100 countries across the UAE, Europe, North America, India, and Africa.
AIR holds 47% of the shisha category market share in the markets it is present it and is the leading business in a market set to grow to $22 billion in 2026. Its portfolio of companies includes Al Fakher, the world’s leading shisha brand; Hookah-Shisha.com, the world’s number one e-commerce platform for hookahs and shisha; Shisha Kartel, a Dubai-based shisha manufacturer; and Shisha.com, a global online community of shisha and hookah users. Advanced Inhalation Rituals’ science program, conducted in partnership with independent accredited laboratories, enables the development innovative products that combine centuries of tradition with cutting edge innovation to minimise harm and maximise enjoyment for millions around the world. The business has consistently outperformed competitors growing at 3x the market rate over the last 10 years, due to heavy investment in innovation, product, and user experience.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241025730501/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom